z-logo
open-access-imgOpen Access
Eculizumab as a bridge to immunosuppressive therapy in severe cold agglutinin disease of anti‐Pr specificity
Author(s) -
Shapiro Roman,
ChinYee Ian,
Lam Selay
Publication year - 2015
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.399
Subject(s) - eculizumab , cold agglutinin disease , medicine , rituximab , hemolysis , autoimmune hemolytic anemia , immunology , complement system , hemolytic anemia , antibody
Key Clinical Message Severe cold agglutinin disease with hemodynamic compromise requires rapid stabilization of the autoimmune hemolytic anemia as a bridge to the immunosuppressive effect of rituximab. Herein, we describe eculizumab treatment of severe complement‐mediated hemolysis in a patient whose hemodynamic status deteriorated in spite of supportive blood transfusions and therapeutic plasma exchange.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here